MIV Therapeutics on its way to many dollars?
MIV THERAPEUTICS ACCEPTS RESIGNATION OF CEO
February 9, 2011, Vancouver, British Columbia (OTC Pinks: MIVI) MIV Therapeutics, Inc. (the “Company” or “MIV”) announced that effective on February 4, 2011, the Board of Directors of MIV accepted Patrick McGowan’s resignation as President, Chief
Executive Officer, Chief Financial Officer, Secretary, Treasurer and as a Director and accepted the consent to act of Chris Chen to serve as President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of the Company.
As a consequence of the above resignation and appointment, Chris Chen is now the Company’s sole director and officer. The Company is now assembling a new board and management team with industry veterans to better facilitate the animal test and clinical
trials in China, as well as the certification of CE Marking in Europe.
The company has also immediately initiated the process of auditing to bring the financial statements up to date so that it can be in the position to accept the new investors from one of the largest medical group from Beijing, China.
About MIV Therapeutics, Inc.
MIV Therapeutics, Inc. is a development stage company in the business of developing next-generation coatings and drug-delivery systems for cardiovascular stents and other implantable medical devices.
Safe Harbour Statements
Except for the statements of historical fact contained herein, the information presented in this news release
constitutes “forward-looking statements” as such term is used in applicable United States and Canadian
laws. These statements relate to analyses and other information that are based on forecasts of future results,
estimates of amounts not yet determinable and assumptions of management. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives,
assumptions or future events or performance (often, but not always, using words or phrases such as
“expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or
“intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be
taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking
statements”. Such forward looking statements involve known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or implied by such forwardlooking
statements.
Forward looking statements are made based on management’s beliefs, estimates and opinions on the date
the statements are made and the Company undertakes no obligation to update forward-looking statements if
these beliefs, estimates and opinions or other circumstances should change, except as required by
applicable law. Although the Company believes that the beliefs, plans, expectations and intentions
contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or
intentions will prove to be accurate. Such forward-looking statements reflect our current views with
respect to future events and are subject to certain risks, uncertainties and assumptions, including, the risks
and uncertainties outlined in our most recent financial statements and reports filed with the United States
Securities and Exchange Commission (the “SEC”) (available at www.sec.gov) and with Canadian
securities administrators (available at www.sedar.com). Investors should consider all of the information set
4200319.1
forth herein and should also refer to the risk factors disclosed in the Company’s periodic reports filed from
time-to-time with the SEC. The Company again cautions investors that the Company is not up-to-date in its
SEC or SEDAR filings. Pink OTC Markets has discontinued the display of quotes on otcmarkets.com for
the Company’s securities because the Company’s securities have been labeled Caveat Emptor (Buyer
Beware) and because adequate current information has not been made available by the Company.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities of the
Company nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction.
Contacts:
MIV Therapeutics, Inc.
Fax: +1 604 357 1640
